Andrew F. Alexis, MD, MPH, Professor of Clinical Dermatology at Weill Cornell Medicine in New York, NY, discusses preliminary study results showing that the newly U.S. Food and Drug Administration-approved biologic, lebrikizumab-lbkz (Ebglyss, Lilly), improves post-inflammatory hyperpigmentation secondary to atopic dermatitis (AD) in people with darker skin tones.
